Belimumab in childhood systemic lupus erythematosus: A review of available data

Belimumab in childhood systemic lupus erythematosus: A review of available data

IntroductionChildhood systemic lupus erythematosus (cSLE) is a complex multisystem autoimmune disease. In 2019, belimumab was approved for the clinical treatment for cSLE, making it the only biological agent approved for cSLE children aged 5 and older in 60 years.ObjectiveTo review emerging evidence...

Full description

Bibliographic Details
Main Authors: Feng Chen, Ying Zheng, Xinying Chen, Zhanfa Wen, Youjia Xu, Jinghua Yang, Kaisi Xu
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-07-01
Series:Frontiers in Immunology
Subjects:
Belimumab
childhood systemic erythematosus (cSLE)
targeted therapy
pediatric lupus
immunology
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2022.940416/full

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2022.940416/full

Similar Items